mately 5 years after completing all treatment, he developed pancytopenia. Extensive workup ruled out relapsed Hodgkin's disease. Myelodysplasia was diagnosed by bone A 38-year-old man developed idiopathic thrombocytopenic purpura (ITP) 8 months following allogeneic marrow biopsy and he underwent successful marrow transplantation from his HLA-matched sister in August BMT while being treated for cGVHD with corticosteroids and tacrolimus (FK506). He received two courses 1994. Transplantation was complicated by pneumonia, veno-occlusive disease, hemolytic-uremic syndrome from of high-dose intravenous immunoglobulin (IvIG) which resulted in transient improvement. A single dose of cyclosporine and mild acute graft-versus-host disease. The hemolytic uremic syndrome resolved on reduced doses of intravenous anti-D immunoglobulin induced a durable response. Anti-D immunoglobulin is better tolerated, cyclosporine, and this medication was eventually discontinued. He later developed extensive chronic graft-versusless complicated to administer, and less expensive than a course of IvIG.
A 38-year-old man with secondary myelodysplasia from alkylating treatment for nodular sclerosing Hodgkin's disDiscussion ease underwent bone marrow transplantation from his HLA-matched sister. He had been well until 7 years preMany studies have documented the effectiveness of intraviously when he was diagnosed with stage IIA nodular muscular and intravenous anti-D immunoglobulin in Rhsclerosing Hodgkin's disease. After a negative staging lappositive patients with ITP. [5] [6] [7] Similar to IvIG, anti-D arotomy with splenectomy, he was treated with mantle immunoglobulin is thought to saturate the reticuloendothelirradiation. The disease recurred 1 year after diagnosis and ial system with antibody coated red cells or work by immuhe received six cycles of MOPP chemotherapy. Approxinomodulation. 7 A dose response curve has been suggested and patients usually respond to subsequent doses. 6 The amount of hemolysis and side-effects are minimal in most mately 70-90% of patients achieve significant platelet
